All In Biotech

Drug Trial Radar · NCT04217473

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Feb 26, 2020

Primary completion

Dec 12, 2023

Study completion Jul 23, 2024

Sponsor

Lead sponsor
TILT Biotherapeutics Ltd.Industry
Sponsor type
Industry
First posted
Jan 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in metastatic melanoma patients.

Conditions

  • Metastatic Melanoma

Interventions

  • TILT-123Biological

    TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with any (serious and non-serious) Adverse Events prior to TIL administration.Time frame: 36 days
  2. Number of Participants with abnormal laboratory values prior to TIL administration.Time frame: 36 days
  3. Number of Participants with vital sign abnormalities prior to TIL administration.Time frame: 36 days
  4. Safety assessed by 12- lead electrocardiograms (ECGs) Adverse Events prior to TIL administration.Time frame: 36 days

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University

    Copenhagen, Denmark

  • CHU Nantes

    Nantes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.